Document details
Selecting and screening recombinant antibody libraries(Review)
Retrieving additional authors...
- Ablynx NV, Technologiepark 4, 9052 Ghent, Belgium
Retrieving additional affiliations...
Abstract
During the past decade several display methods and other library screening techniques have been developed for isolating monoclonal antibodies (mAbs) from large collections of recombinant antibody fragments. These technologies are now widely exploited to build human antibodies with high affinity and specificity. Clever antibody library designs and selection concepts are now able to identify mAb leads with virtually any specificity. Innovative strategies enable directed evolution of binding sites with ultra-high affinity, high stability and increased potency, sometimes to a level that cannot be achieved by immunization. Automation of the technology is making it possible to identify hundreds of different antibody leads to a single therapeutic target. With the first antibody of this new generation, adalimumab (Humira, a human IgG1 specific for human tumor necrosis factor (TNF)), already approved for therapy and with many more in clinical trials, these recombinant antibody technologies will provide a solid basis for the discovery of antibody-based biopharmaceuticals, diagnostics and research reagents for decades to come. © 2005 Nature Publishing Group.
Indexed keywords
| Engineering controlled terms: | BiotechnologyDiagnosisImmunizationTumors |
|---|---|
| Engineering uncontrolled terms: | Antibody fragmentsAntibody librariesResearch reagentsTumor necrosis factor (TNF) |
| Engineering main heading: | Monoclonal antibodies |
| EMTREE drug terms: | abt 874abthraxadalimumabadecatumumabalpha granulocyte macrophage colony stimulating factor receptor alphaazd 3102belimumabbertilimumabcat 192bdx 2240gc 1008imc 1121bimc 11f8imc a12interleukin 13 antibodymedi 524monoclonal antibodymonoclonal antibody 1121monoclonal antibody 14b7monoclonal antibody b4 12monoclonal antibody c11l34monoclonal antibody c65monoclonal antibody g8monoclonal antibody H6monoclonal antibody l19monoclonal antibody lm 609monoclonal antibody RFB4monoclonal antibody sme3mor 102myo 029numaxpalivizumabrecombinant antibodytumor necrosis factorunclassified drugunindexed drug |
| EMTREE medical terms: | allergic rhinitisAlzheimer diseaseanthraxantibody affinityantibody combining siteantibody isolationantibody screeningantibody specificityautoimmune diseaseautomationB lymphocytebacterial strainbacteriophagebinding sitebreast cancerclinical trialdiagnostic proceduredrug potencydrug screeningdrug stabilitydrug targetingenzyme linked immunosorbent assayEscherichia coligenotypehumanimmunizationlung fibrosislymphomamedical technologymicrobial activitymultiple sclerosismuscular dystrophynonhumanphage displayphenotypepolymerase chain reactionpriority journalprostate cancerprotein DNA bindingreviewrheumatoid arthritisribosomesensitivity and specificitysolid tumorStaphylococcus aureussystemic sclerosisvirus infectionyeast cellZymomonas mobilis |
| MeSH: | AnimalsAntibodiesAntibodies, MonoclonalAutomationBacteriaBinding SitesBiophysicsEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin FragmentsMutagenesisPeptide LibraryRecombinant ProteinsRibosomesRNA, MessengerSaccharomyces cerevisiaeTumor Necrosis Factor-alpha |
| Species Index: | Bacteria (microorganisms)Escherichia coliStaphylococcus aureusZymomonas mobilis |
Chemicals and CAS Registry Numbers:
adalimumab, 331731-18-1; adecatumumab, 503605-66-1; belimumab, 356547-88-1; bertilimumab, 375348-49-5; palivizumab, 188039-54-5;
adalimumab; Antibodies; Antibodies, Monoclonal; Immunoglobulin Fragments; Peptide Library; Recombinant Proteins; RNA, Messenger; Tumor Necrosis Factor-alpha
Drug tradename:
- abt 874, Abbott, United States,
- abthrax, Human Genome Sciences, United States,
- azd 3102, Astra Zeneca,
- cat 192b, Genzyme, United States,
- cat 213, Cambridge Antibody Technology, United States,
- cat 354, Cambridge Antibody Technology, United States,
- dx 2240, Dyax,
- gc 1008, Genzyme, United States,
- humira, Abbott, United States,
- imc 1121b, Imclone,
- imc 11f8, Imclone,
- imc a12, Imclone,
- lymphostat b, Human Genome Sciences, United States,
- medi 522, Medarex, United States,
- medi 524, Medimmune,
- mor 102, Morphosys,
- mt 201, Micromet,
- myo 029, Wyeth, United States,
- numax, Medimmune,
- synagis, Medimmune, United States,
- vitaxin, Medarex, United States
Manufacturers:
Drug manufacturer:
Abbott, United States;
Amrad;
Astra Zeneca;
Cambridge Antibody Technology, United States;
Dyax;
Genentech, United States;
Genzyme, United States;
GPC Biotech;
Human Genome Sciences, United States;
Imclone, United States;
massachusetts institute of technology, United States;
Medarex, United States;
Medimmune, United States;
Micromet;
Morphosys;
National Cancer Institute, United States;
scripps research institute, United States;
University of California, United States;
university of maadtricht, Netherlands;
University of Texas, United States;
unversity of illinois, United States;
unversity of siena, Italy;
unversity of zurich;
Wyeth, United States
- ISSN: 10870156
- CODEN: NABIF
- Source Type: Journal
- Original language: English
- DOI: 10.1038/nbt1126
- PubMed ID: 16151404
- Document Type: Review
Hoogenboom, H.R.; Ablynx NV, Technologiepark 4, Belgium;
© Copyright 2008 Elsevier B.V., All rights reserved.
© MEDLINE® is the source for the MeSH terms of this document.
Cited by 657 documents
Sanada, H.
, Kobayashi, K.
, Oyama, K.
(2018) Scientific Reports
(2018) Scientific Reports
Shi, Y.Z.
, Xiong, S.
, Zhang, Y.
(2018) Nature Communications
(2018) Nature Communications
Schröter, C.
, Beck, J.
, Krah, S.
(2018) Molecular Biotechnology
(2018) Molecular Biotechnology
View details of all 657 citations